Novo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia.

UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.

Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Elron Electronics Ltd. (TASE:ELRN) have signed an agreement under which Roche will acquire 100% of Medingo Ltd., a majority-owned subsidiary of the Elron group.

Genzyme Corporation (Nasdaq: GENZ) reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound.

Data from the two-year FREEDOMS study showed that Gilenia* 0.5 mg reduced annual relapse rates (ARR) by 62% for treatment naïve patients compared to placebo. For patients previously receiving other treatments, the annual relapse rates were reduced by 44%.

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and CureDM Group Holdings, LLC, announced today a global license agreement on a novel human peptide, Pancreate™, which could restore a patients' ability to produce insulin and other pancreatic hormones in both type 1 and type 2 diabetes.